Diagnostic Criteria for Uterine Sarcoma: Review of the Literature

Author(s)	allae eddine bouchaib, SOUKAINA LAAREJ, abdellah BABAHABIB, moulay el mehdi ELHASSANI, jaouad KOUACH
Country	Morocco
Abstract	Uterine leiomyosarcomas are rare and have a poor prognosis, particularly at the metastatic stage. The rarity of this tumor justiﬁe that patients be referred to referral centers aﬁn order to have optimal diagnostic and therapeutic management. Anatomopathologic diagnosis is based on the demonstration of three features: necrosis, cytologic atypia, and mitoses within a smooth muscle proliferation. Chemotherapy probably has a place in the adjuvant management. In locally advanced or metastatic forms, the prognosis is poor, with an overall survival of about 12-14 months despite first-line polychymic therapy that gives response rates of about 30%. Anti-angiogenic drugs and hormone therapy have their place in the therapeutic arsenal. Multimodal management can improve the prognosis of some patients
Keywords	uterine leiomyosarcoma, rare disease, chemotherapy, multidisciplinarity
Field	Medical / Pharmacy
Published In	Volume 5, Issue 2, March-April 2023
Published On	2023-04-16
DOI	https://doi.org/10.36948/ijfmr.2023.v05i02.2472
Short DOI	https://doi.org/gr5qsx

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research